previou
clinic
trial
assess
treatment
unstabl
type
diabet
demonstr
restor
pancreat
function
allogen
islet
transplant
univers
alberta
report
transplant
allogen
purifi
islet
product
result
sustain
cpeptid
level
improv
glycem
control
prevent
hypoglycemia
seven
subject
type
diabet
result
later
confirm
brennan
et
al
multicent
trial
report
followup
seven
subject
one
subject
experienc
graft
failur
year
transplant
remain
six
continu
sustain
cpeptid
level
improv
glycem
control
episod
sever
hypoglycemia
opportunist
infect
lymphoma
report
although
signific
progress
made
sinc
initi
trial
develop
pathway
cellular
therapi
requir
converg
toward
regulatori
guidelin
clinic
trial
design
manufactur
differ
variou
process
facil
prevent
comparison
clinic
result
across
center
make
difficult
deriv
overal
conclus
limit
islet
transplant
use
medic
practic
factor
affect
qualiti
islet
product
includ
organ
donor
accept
criteria
organ
recoveri
techniqu
cold
ischemia
time
organ
preserv
transport
solut
method
islet
isol
purif
cultur
previous
report
protocol
prospect
multicent
singlearm
pivot
phase
trial
conduct
eight
academ
institut
north
america
clinic
trial
reg
wwwclinicaltrialsgov
trial
evalu
safeti
toler
efficaci
purifi
human
pancreat
islet
phpi
product
defin
popul
subject
type
diabet
support
product
licensur
us
trial
conduct
divis
allergi
immunolog
transplantationn
institut
allergi
infecti
diseas
daitniaid
us
investig
new
drug
applic
clinic
trial
applic
canada
manufactur
inform
submit
daitniaidsponsor
us
drug
master
file
chemistri
manufactur
control
monitor
committe
cmc
mc
repres
manufactur
facil
daitniaid
respons
harmon
manufactur
process
includ
inprocess
control
qualif
manufactur
facil
definit
product
specif
qualiti
oversight
articl
describ
manufactur
process
inprocess
lot
releas
test
result
clinic
lot
transplant
subject
enrol
trial
product
manufactur
transplant
institut
report
result
first
success
standard
manufactur
process
allogen
phpi
product
execut
multipl
facil
transplant
support
pivot
trial
clinic
islet
transplant
cit
standard
oper
procedur
sop
master
product
batch
record
mpbr
develop
product
manufactur
public
avail
clinic
outcom
report
elsewher
arriv
donor
pancrea
manufactur
facil
accept
criteria
verifi
tabl
sampl
preserv
solut
taken
steril
test
excess
pancrea
tissu
remov
pancrea
weigh
initi
weight
pancrea
decontamin
place
hank
balanc
salt
solut
contain
gl
cefazolin
povidon
iodin
solut
pancrea
divid
neck
separ
head
bodi
tail
cannula
place
main
pancreat
duct
section
basi
initi
pancrea
weight
volum
cit
enzym
solut
determin
pancrea
perfus
one
three
enzym
blend
solut
contain
collagenas
proteas
tabl
enzym
lot
qualifi
three
cit
manufactur
assess
enzym
activ
introduct
product
manufactur
pancrea
segment
distend
intraduct
perfus
cold
cit
enzym
solut
either
manual
control
perfus
perfus
occur
min
mmhg
follow
min
mmhg
final
trim
pancrea
weight
calcul
subtract
weight
tissu
trim
perfus
initi
pancrea
weight
perfus
pancrea
cut
piec
place
ricordi
digest
chamber
biorep
technolog
inc
miami
lake
fl
tissu
digest
began
recircul
enzym
solut
phase
dissoci
pancrea
progress
follow
dilut
phase
phase
enzym
neutral
cool
dilut
fresh
rpmi
medium
recircul
phase
circuit
prime
cit
enzym
solut
temperatur
set
flow
rate
set
mlmin
set
temperatur
reach
reduc
mlmin
freed
islet
elut
dilut
buffer
collect
sampl
taken
throughout
digest
assess
dtz
stain
determin
time
switch
phase
phase
decis
switch
dilut
base
number
islet
percent
free
islet
percent
fragment
islet
dilut
phase
flow
rate
increas
back
mlmin
temperatur
reduc
larg
number
embed
islet
observ
sampl
digest
product
temperatur
maintain
dilut
complet
minim
tissu
remain
chamber
islet
observ
dtzstain
remain
tissu
eluat
contain
islet
pool
centrifug
wash
cold
cit
wash
solut
resuspend
cold
cit
purif
solut
twentyf
millilit
less
digest
tissu
layer
iodixanolbas
continu
densiti
gradient
rang
gml
centrifug
rpm
cobe
cell
processor
terumo
bct
lakewood
co
twelv
gradient
fraction
collect
ml
conic
tube
prefil
ml
cmrl
supplement
cit
modif
solut
mediatech
manassa
va
islet
puriti
fraction
estim
dtz
stain
purifi
fraction
classifi
high
middl
low
puriti
puriti
pool
islet
present
fraction
puriti
supplementari
purif
perform
use
biocol
biochrom
ag
berlin
germani
polysucros
discontinu
gradient
mediatech
optiprep
nycomedtakeda
osaka
japan
puriti
fraction
obtain
supplementari
purif
assess
dtz
stain
fraction
combin
fraction
equival
puriti
obtain
use
iodixanolbas
gradient
point
forward
high
medium
lowpur
fraction
process
separ
combin
cultur
immedi
fill
infus
bag
purifi
islet
cultur
h
nontreat
vent
flask
sarstedt
ag
co
germani
islet
equival
ieq
ml
cit
cultur
media
highpur
islet
fraction
cultur
first
h
remain
time
middl
lowpur
fraction
cultur
time
previous
report
media
remov
first
h
fresh
media
ad
cultur
islet
tissu
collect
wash
pool
resuspend
ml
cit
transplant
media
accord
islet
fraction
puriti
rang
settl
tissu
volum
estim
aspir
pellet
high
middl
lowpur
fraction
glass
pipett
allow
aspir
sediment
graviti
min
combin
total
settl
tissu
volum
ml
puriti
fraction
pool
singl
infus
bag
total
settl
tissu
volum
ml
tissu
divid
two
three
infus
bag
maximum
tissu
volum
mlbag
pool
tissu
infus
bag
allow
sediment
wash
resuspend
ml
cit
transplant
media
final
product
maintain
room
temperatur
transplant
within
h
bag
fill
sampl
lot
releas
test
obtain
fill
infus
bag
phpi
final
product
test
assess
product
safeti
puriti
ident
potenc
steril
biolog
potenc
result
avail
time
lot
releas
lot
releas
transplant
use
interim
coa
icoa
supplementari
data
safeti
assess
time
releas
includ
microbi
contamin
gram
stain
endotoxin
use
limulu
amoebocyt
lysat
endosafept
charl
river
charleston
sc
final
coa
issu
steril
postcultur
gsir
test
result
becam
avail
tabl
steril
test
perform
compliant
section
code
feder
regul
titl
preemptiv
plan
includ
criteria
report
product
contamin
contamin
lot
need
transplant
clinic
reason
agre
food
drug
administr
puriti
phpi
product
defin
histolog
total
ieq
per
millilit
total
settl
tissu
volum
viabil
assess
stain
fdapi
sigmaaldrich
st
loui
mo
express
percent
viabl
cell
among
consecut
islet
dtz
stain
use
identif
islet
quantif
ieq
puriti
determin
categor
size
rang
biolog
potenc
determin
gsir
elisa
quantit
concentr
insulin
secret
vitro
islet
respons
stimul
low
mmoll
high
mmoll
glucos
concentr
result
express
stimul
index
recoveri
defin
quantiti
ieq
retriev
manufactur
process
express
ieq
per
gram
trim
pancrea
process
yield
refer
proport
ieq
recov
rel
start
ieq
continu
variabl
display
number
observ
mean
sd
median
interquartil
rang
iqr
categor
variabl
display
number
percent
relationship
donor
characterist
ieq
recoveri
analyz
stepwis
regress
comparison
variabl
among
enzym
solut
manufactur
center
perform
use
f
test
statist
signific
defin
p
sa
window
version
softwar
sa
institut
cari
nc
use
data
manag
statist
analys
tabl
summar
pancrea
donor
physic
characterist
caus
death
preserv
method
cold
ischemia
time
final
recoveri
ieq
correl
donor
sex
bmi
p
respect
donor
pancrea
characterist
significantli
relat
ieq
recoveri
adjust
donor
sex
bmi
differ
donor
bmi
among
center
led
differ
weight
trim
pancrea
total
ieq
recov
per
pancrea
pairwis
comparison
among
center
ieq
recoveri
per
gram
trim
pancrea
reveal
signific
differ
adjust
multipl
comparison
lot
manufactur
use
collagenas
proteas
tabl
mean
cit
enzym
solut
volum
use
perfus
ml
rang
ml
mean
perfus
time
min
signific
differ
among
enzym
blend
final
recoveri
ieq
per
gram
trim
pancrea
mean
digest
time
recircul
phase
min
rang
min
decis
switch
dilut
phase
base
visual
examin
sampl
digest
tissu
collect
ricordi
chamber
follow
factor
consid
total
amount
digest
tissu
sampl
estim
total
number
islet
percent
free
islet
percent
fragment
islet
mean
durat
phase
min
rang
min
median
iqr
pack
tissu
volum
phase
ml
contain
ieq
repres
step
recoveri
ieqg
trim
pancrea
tabl
islet
purif
perform
continu
densiti
gradient
centrifug
cobe
cell
processor
maximum
tissu
volum
purifi
cobe
run
ml
cobe
oper
perform
lot
manufactur
transplant
requir
two
three
one
four
cobe
run
respect
islet
purif
digest
tissu
postpurif
islet
recoveri
total
ieq
ieq
repres
ieqg
trim
pancrea
cultur
fraction
combin
base
rel
puriti
high
medium
low
determin
dtz
stain
purif
step
median
yield
islet
present
postdigest
intermedi
product
tabl
purifi
islet
cultur
h
transplant
first
h
highpur
islet
fraction
incub
middl
lowpur
islet
fraction
incub
previous
describ
fraction
cultur
remaind
cultur
period
median
total
islet
count
postcultur
ieq
repres
total
islet
recoveri
ieqg
trim
pancrea
median
islet
yield
cultur
step
median
total
process
yield
calcul
postdigest
postcultur
tabl
phpi
final
product
releas
basi
result
report
icoa
supplementari
data
phpi
product
lot
defin
purifi
pancreat
islet
isol
singl
purif
run
singl
deceas
donor
pancrea
administ
singl
recipi
twentytwo
subject
receiv
one
dose
phpi
intraport
infus
receiv
two
three
dose
respect
addit
detail
dose
first
second
third
infus
includ
supplementari
data
initi
transplant
requir
dose
ieqkg
recipi
bodi
weight
bw
second
third
requir
dose
ieqkg
recipi
bw
tabl
median
total
phpi
dose
per
subject
ieqkg
rang
ieqkg
subject
achiev
clinic
success
phpi
lot
releas
transplant
n
n
n
infus
bag
median
settl
tissu
volum
ml
contain
ieqkg
recipi
bw
concentr
ieqml
settl
tissu
median
viabil
highpur
sampl
median
gsir
stimul
index
tabl
phpi
lot
gram
stain
neg
endotoxin
concentr
endotoxin
unitskg
recipi
bw
steril
test
perform
sampl
preserv
solut
final
product
supplementari
data
preserv
solut
sampl
contamin
skin
saprophyt
contain
candida
albican
final
product
steril
test
lot
show
skin
saprophyt
lot
contain
c
albican
lot
report
presenc
c
albican
preserv
solut
per
cit
consortium
sitespecif
procedur
case
site
investig
immedi
notifi
subject
receiv
lot
contamin
c
albican
receiv
fluconazol
prophylact
none
recipi
six
lot
exhibit
sign
symptom
infect
posttransplant
advers
effect
attribut
investig
product
report
recipi
lot
met
interim
lot
releas
criteria
transplant
posit
steril
test
result
report
six
product
lot
two
lot
fail
gsir
specif
lot
met
final
releas
criteria
method
largescal
isol
purif
adult
human
pancreat
islet
substanti
improv
past
three
decad
result
major
collabor
effort
among
sever
center
north
america
europ
advanc
islet
process
technolog
immunosuppress
immunomodul
peritranspl
antiinflammatori
strategi
contribut
progress
improv
clinic
result
howev
lack
standard
islet
process
method
may
contribut
variabl
outcom
across
center
reduc
abil
compar
result
even
clinic
protocol
immunosuppress
regimen
use
previous
report
differ
outcom
among
center
highlight
challeng
manufactur
process
pancreat
islet
addit
relat
immunosuppress
manag
islet
allotransplant
edmonton
trial
conduct
nine
center
result
variabl
success
rate
primari
end
point
case
primari
nonfunct
occur
two
three
center
subject
achiev
primari
end
point
islet
product
transplant
immedi
process
may
allow
time
evalu
qualiti
product
given
previou
experi
minim
risk
primari
nonfunct
purifi
islet
cultur
permit
qualiti
control
product
releas
transplant
qualiti
islet
product
affect
donor
characterist
organ
recoveri
preserv
islet
isol
purif
cultur
method
cit
investig
recogn
need
major
effort
standard
phpi
manufactur
process
allow
meaning
comparison
clinic
trial
outcom
across
site
investig
also
recogn
need
defin
stringent
donor
select
criteria
defin
develop
process
improv
base
acquir
experi
would
consist
yield
highqual
islet
product
report
method
result
common
manufactur
protocol
repres
converg
sever
year
teamwork
eight
academ
institut
optim
standard
process
criteria
test
method
across
islet
transplant
center
major
standard
effort
undertaken
ensur
product
process
consist
test
method
reproduc
across
particip
manufactur
cit
collabor
effort
result
implement
defin
set
critic
process
paramet
inprocess
control
phpi
product
reflect
common
mpbr
sop
execut
eight
cit
process
facil
among
key
raw
materi
identifi
donor
pancrea
enzym
blend
critic
compon
phpi
manufactur
process
wide
use
enzym
manufactur
islet
product
becam
unavail
unforeseen
limit
forc
group
reevalu
test
qualifi
addit
proteolyt
replac
enzym
cit
effort
result
success
identif
test
new
enzym
blend
manufactur
center
result
present
show
enzym
use
digest
yield
lot
met
product
specif
therefor
could
use
manufactur
phpi
product
trial
potenc
assess
viabil
ident
islet
determin
fdapi
dtz
stain
respect
cmc
mc
develop
standard
gsir
elisa
qualiti
control
vitro
assay
potenc
assess
phpi
product
gsir
assay
provid
quantit
measur
biolog
activ
determin
amount
insulin
releas
respons
glucos
stimul
tabl
conduct
protocol
lot
releas
basi
icoa
met
lot
releas
specif
supplementari
data
previous
state
gsir
result
final
product
avail
transplant
addit
studi
may
determin
whether
gsir
becom
compon
matrix
function
assay
lot
releas
clinic
trial
result
show
phpi
product
welltoler
safe
effect
specif
type
diabet
popul
result
obtain
despit
rang
donor
characterist
bmi
donor
age
year
cold
ischemia
time
h
median
phpi
dose
rang
ieqkg
report
first
success
standard
manufactur
defin
complex
biolog
cellular
product
treatment
type
diabet
hypoglycemia
across
multipl
manufactur
facil
licenseen
trial
cgmp
manufactur
process
defin
common
cit
document
yield
product
lot
met
prespecifi
criteria
safeti
puriti
potenc
ident
result
show
cit
manufactur
achiev
consist
reproduc
result
across
particip
center
case
primari
nonfunct
observ
transplant
phpi
lot
manufactur
clinic
data
gener
studi
avail
cit
noncit
site
facilit
licensur
food
drug
administr
product
licensur
import
improv
patient
access
thirdparti
coverag
phpi
transplant
facilit
develop
secondgener
islet
product
eg
stem
cell
xenogen
encapsul
